The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and ...

Twelve RCTs were included in our meta-analysis, with a total of 3,565 patients. We observed that third-generation EGFR-TKIs and first-generation EGFR-TKIs combined with antiangiogenic drugs provided a ...

“We postulate that these observations may provide novel opportunities for therapeutic interventions for EGFR driven cancers.” “We postulate that BUB1 helps in the formation and stabilization of EGFR ...

Amivantamab targets EGFR and MET receptors, offering a novel approach for mCRC treatment, especially in RAS and BRAF wild-type patients. The OrigAMI-2 study compares amivantamab with standard ...

What Is It, and Why Does It Matter? Rybrevant Faspro is a new under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has now approved it in ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

(A) The AlphaFold protein structure of GPER from the public database (https://alphafold.com/entry/Q99527). (B) E2, the GPER-specific agonist G1, SERMs, and SERDs ...